Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Dow
Moodys
Cantor Fitzgerald
McKesson
UBS
Fish and Richardson
Fuji
US Army

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZEJULA

« Back to Dashboard

Clinical Trials for Zejula

Trial ID Title Status Sponsor Phase Summary
NCT03207347 A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001) Not yet recruiting Tesaro, Inc. Phase 2 This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA double-strand break repair pathway genes.
NCT03207347 A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001) Not yet recruiting University of Florida Phase 2 This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA double-strand break repair pathway genes.
NCT03307785 Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 Not yet recruiting Tesaro, Inc. Phase 1 Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study. Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
NCT03308942 Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer Recruiting Covance Phase 2 A phase 2 study to evaluate the efficacy of niraparib alone and in combination with PD-1 inhibitor in three cohorts: all histologies with high PD-L1 expression (greater than 50% TPS), all histologies low PD-L1 expression (1-49% TPS), and squamous cell lung cancer. [TPS=Tumor Proportion Score]
NCT03308942 Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer Recruiting DrugDev Phase 2 A phase 2 study to evaluate the efficacy of niraparib alone and in combination with PD-1 inhibitor in three cohorts: all histologies with high PD-L1 expression (greater than 50% TPS), all histologies low PD-L1 expression (1-49% TPS), and squamous cell lung cancer. [TPS=Tumor Proportion Score]
NCT03308942 Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer Recruiting INC Research Phase 2 A phase 2 study to evaluate the efficacy of niraparib alone and in combination with PD-1 inhibitor in three cohorts: all histologies with high PD-L1 expression (greater than 50% TPS), all histologies low PD-L1 expression (1-49% TPS), and squamous cell lung cancer. [TPS=Tumor Proportion Score]
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zejula

Condition Name

Condition Name for Zejula
Intervention Trials
Solid Tumor 2
Ovarian Cancer 2
BRCA2 Gene Mutation 1
Metastatic Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zejula
Intervention Trials
Ovarian Neoplasms 2
Neoplasms, Glandular and Epithelial 2
Neoplasms 2
Mesothelioma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zejula

Trials by Country

Trials by Country for Zejula
Location Trials
United States 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zejula
Location Trials
Florida 4
Massachusetts 3
Texas 3
California 3
Tennessee 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zejula

Clinical Trial Phase

Clinical Trial Phase for Zejula
Clinical Trial Phase Trials
Phase 3 1
Phase 2 4
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zejula
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zejula

Sponsor Name

Sponsor Name for Zejula
Sponsor Trials
Tesaro, Inc. 8
DrugDev 1
European Network of Gynaecological Oncological Trial Groups (ENGOT) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zejula
Sponsor Trials
Industry 10
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Mallinckrodt
Citi
McKesson
US Army
Deloitte
Teva
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.